Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.
about
A Review of Management of Inflammation in the HIV PopulationSwitch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical PracticeInflammation, Immune Activation, and Antiretroviral Therapy in HIVAssociation of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infectionElevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort StudyDifferential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors.Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV InfectionInflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected AdultsAddressing Antiretroviral Therapy-Associated Drug-Drug Interactions in Patients Requiring Treatment for Opportunistic Infections in Low-Income and Resource-Limited Settings.Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.Telmisartan Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued ART Alone.
P2860
Q28078962-D4E73572-495E-404A-A589-8D5F443D8715Q28553066-F604FEA0-9C08-4DFB-8EE5-67B3FA76E5F2Q33912595-7EB50470-A066-4AE4-B26D-DA85A4E0D20CQ34557631-6698CB99-648F-4D7F-9041-D6613BBDACD5Q34784783-17A383F5-DB0C-421E-897F-677CD3C4BD33Q35814594-9345AD38-44CD-445C-9D4C-76BF739C7145Q35965242-1233A724-6AAC-48EB-A83D-7AD935AD8574Q35974422-B25F64A0-AE19-4D77-988B-82AB85E7AB05Q36063953-695C9D70-CD3F-4067-9288-6D7374104A8FQ36654972-B3521347-0531-4A65-A0EF-B7F85B982C4AQ37003062-9853FFA2-8055-4C10-A4B6-7B264BDEAFDEQ40051462-35BC8CAA-E21C-452B-B6F3-ADFEDE7DC369Q40145206-C6544299-5915-40A2-8E92-61AA008F66C1Q41736369-695E94E1-D59F-4BB2-8E66-90F65D8F7CE9Q51755304-70A7ADFB-7889-4BC2-94B7-F980FEE250E8
P2860
Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@ast
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@en
type
label
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@ast
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@en
prefLabel
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@ast
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@en
P2093
P2860
P356
P1433
P1476
Switch to raltegravir decrease ...... se and Fat Accumulation Trial.
@en
P2093
G A McComsey
J S Currier
S A Stramotas
P2860
P304
P356
10.1111/HIV.12128
P50
P577
2014-02-10T00:00:00Z